LNP

HDT Bio Receives $749,000 EZBAA Contract and Partners with BARDA Under Project NextGen's Enabler's Program

Retrieved on: 
Tuesday, January 23, 2024
LION, Development, Nextgen, RNA, Partnership, CGMP, Administration, Cancer, Infection, Enabling, Project, Therapy, Transport, Human services, Vaccine, LNP

Through this partnership, HDT Bio has received a $749,000 contract, which will support proof-of-concept studies for on-demand manufacturing and release processes that use HDT Bio's LION™ formulation for RNA vaccine production.

Key Points: 
  • Through this partnership, HDT Bio has received a $749,000 contract, which will support proof-of-concept studies for on-demand manufacturing and release processes that use HDT Bio's LION™ formulation for RNA vaccine production.
  • The Project NextGen Enabler's program aims to advance next generation vaccine and therapeutics technologies, including the development of innovative cGMP manufacturing of vaccines that decrease costs, speed production, increase efficacy, and improve access.
  • "We are honoured to collaborate with BARDA through the receipt of this award under the Project NextGen Enabler's program.
  • The funding will also support development of novel microfluidic mixing chips that enable automated, rapid-release, assay-free preparation of vaccines.

Genevant Sciences to Collaborate with Tome Biosciences to Develop Gene Editing Therapeutic for Rare Liver Disorder

Retrieved on: 
Tuesday, January 16, 2024
LNP, PGI, Gene editing

VANCOUVER, British Columbia, and BASEL, Switzerland, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and a robust and expansive lipid nanoparticle (LNP) patent portfolio, today announced it has entered into a collaboration and nonexclusive license agreement with Tome Biosciences to combine its proprietary LNP technology with Tome’s programmable genomic integration (PGI) technology to develop an in vivo gene editing treatment for an undisclosed rare monogenic liver disorder.

Key Points: 
  • VANCOUVER, British Columbia, and BASEL, Switzerland, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and a robust and expansive lipid nanoparticle (LNP) patent portfolio, today announced it has entered into a collaboration and nonexclusive license agreement with Tome Biosciences to combine its proprietary LNP technology with Tome’s programmable genomic integration (PGI) technology to develop an in vivo gene editing treatment for an undisclosed rare monogenic liver disorder.
  • “Successful delivery is critical to realizing the promise of next-generation gene editing approaches like Tome’s, highlighting the importance of world-class LNP technology,” said Pete Lutwyche, Ph.D., President and Chief Executive Officer of Genevant Sciences.
  • “We are pleased to be working with Tome to bring its innovative gene editing technology to patients.”
    “We look forward to collaborating with Genevant, a leader in the LNP space, to advance this important PGI program,” said Rahul Kakkar, Chief Executive Officer of Tome.
  • The terms of the agreement and a completed evaluation agreement provide for a total deal value for Genevant of $114.3 million, as well as tiered royalties on future product sales.

Unchained Labs rolls out the red carpet for the king of LNP characterization…Stunner!

Retrieved on: 
Tuesday, January 9, 2024
Vivisection, Protein, Atomic mass, Marketing, LNP, UV, SVP, Fine chemical

Enter Stunner, the first instrument to pull all this LNP data together from one tiny 2 µL sample.

Key Points: 
  • Enter Stunner, the first instrument to pull all this LNP data together from one tiny 2 µL sample.
  • In the same 2-minute experiment it uses UV/Vis with precision of 1% and accuracy of 2% to quantify the total payload present.
  • "Our new Stunner really is the cream of the crop for LNP characterization.
  • It measures exactly what researchers need to find the best formulation and develop a robust process to make great LNPs," said Taegen Clary, SVP of Marketing at Unchained Labs.

Unchained Labs rolls out the red carpet for the king of LNP characterization…Stunner!

Retrieved on: 
Tuesday, January 9, 2024
Vivisection, Protein, Atomic mass, Marketing, LNP, UV, SVP, Fine chemical

Enter Stunner, the first instrument to pull all this LNP data together from one tiny 2 µL sample.

Key Points: 
  • Enter Stunner, the first instrument to pull all this LNP data together from one tiny 2 µL sample.
  • In the same 2-minute experiment it uses UV/Vis with precision of 1% and accuracy of 2% to quantify the total payload present.
  • "Our new Stunner really is the cream of the crop for LNP characterization.
  • It measures exactly what researchers need to find the best formulation and develop a robust process to make great LNPs," said Taegen Clary, SVP of Marketing at Unchained Labs.

NanoImaging Services Appoints John Rigg as Chief Executive Officer

Retrieved on: 
Monday, January 8, 2024
LNP, Protein, Immune electron microscopy, Liverpool John Moores University, Biotechnology, Drug development, QA/QC, Ventria Bioscience, Quality control, SAN, Eli Lilly and Company, Nanoparticle, Growth, General partnership

SAN DIEGO, Jan. 8, 2024 /PRNewswire/ -- NanoImaging Services ("NIS"), the leading provider of cryo-electron microscopy ("cryo-EM") services to the pharmaceutical and biotechnology communities, announced today the appointment of John Rigg as Chief Executive Officer (CEO).

Key Points: 
  • SAN DIEGO, Jan. 8, 2024 /PRNewswire/ -- NanoImaging Services ("NIS"), the leading provider of cryo-electron microscopy ("cryo-EM") services to the pharmaceutical and biotechnology communities, announced today the appointment of John Rigg as Chief Executive Officer (CEO).
  • Brian Conkle, who served as interim CEO in 2023, will remain at NIS as Chief Operating Officer.
  • Mr. Rigg brings over 20 years of leadership experience within the pharmaceutical and biomanufacturing industries to NIS.
  • Most recently, he served as Chief Executive Officer of Exelead Biopharma, a biopharmaceutical contract development and manufacturing organization specializing in complex injectable formulations, including lipid nanoparticle (LNP) based drug delivery.

ElevateBio to Highlight Growth of its Genetic Medicine Business Driven By Gene Editing and Manufacturing Partnerships at the 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Monday, January 8, 2024
Research, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, Other Science, Science, Oncology, LNP, RNA, Liver, Conference, Ecosystem, Partnership, Gene editing, Autoimmunity, Messenger, Small RNA, CRISPR, CGMP, DNA, Brain, HSC, Therapy, DSM-IV codes, Novo Nordisk, GMP, University, RT, Library, Viral, Artificial intelligence, Deletion, COGS, Gene, Engineering, Genome, Mountaineering, Good manufacturing practice, Bone marrow, Automation, BLA, Vaccine

Chairman and Chief Executive Officer, David Hallal, will provide a business update at the 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024 at 9:30 am PT.

Key Points: 
  • Chairman and Chief Executive Officer, David Hallal, will provide a business update at the 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024 at 9:30 am PT.
  • Announced two transformative R&D collaborations with Moderna and Novo Nordisk to discover and develop gene editing therapeutics.
  • BaseCamp is ElevateBio’s genetic medicine process development and cGMP business enabling biopharmaceutical partners with its end-to-end capabilities.
  • Developed additional C-base editors for gene knock-outs in novel cell therapies and A-base editors for in vivo gene editing therapeutics.

Arbutus Announces 2024 Corporate Objectives and Provides Financial Update

Retrieved on: 
Monday, January 8, 2024
LNP, RNA interference, AASLD, Virology, HBV, Vaccine, Court, Nivolumab, Congress, Clinical trial, Pharmacokinetics, PD, Expert witness, Arbutus, COVID-19, EASL, CFBV, Interim, Investment, Patient, Safety, HBsAg, PD-L1, Pharmaceutical industry

Arbutus plans to announce end-of-treatment data from this trial in the first half of 2024.

Key Points: 
  • Arbutus plans to announce end-of-treatment data from this trial in the first half of 2024.
  • Arbutus plans to announce end-of-treatment data from this portion of the trial in the first half of 2024.
  • Arbutus expects to report preliminary data from the healthy subject portion of this clinical trial, including target engagement and receptor occupancy data, in the first half of 2024.
  • With respect to the Moderna lawsuit, fact discovery is currently on-going with the claim construction hearing scheduled for February 8, 2024.

CRISPR Therapeutics Highlights Strategic Priorities and 2024 Outlook

Retrieved on: 
Monday, January 8, 2024
LNP, Liver, Gene editing, Risk, Autoimmunity, Moyamoya disease, FDA, CRSP, SLE, Lupus, Stem cell, ANGPTL3, Pharmacology, CHMP, Kingdom, Guide, CRISPR Therapeutics, Vertex, PDUFA, Human, Pharmacokinetics, RNA, EMA, CRISPR, Therapy, Genetics, Vertex Pharmaceuticals, Bill, Patient, CD70, SCD, T1D, Sickle cell disease, Partnership, Hypertriglyceridemia, Research, Insulin, Diabetes, Hospital, Clinical trial, GMP, European Medicines Agency, Growth, Committee, CD19, TDT, Cardiovascular disease, Good, ADC, Pharmaceutical industry

ZUG, Switzerland and BOSTON, Jan. 08, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today highlighted its strategic priorities and 2024 outlook as the Company enters its next phase of growth.

Key Points: 
  • ZUG, Switzerland and BOSTON, Jan. 08, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today highlighted its strategic priorities and 2024 outlook as the Company enters its next phase of growth.
  • Exa-cel is the first therapy to emerge from a strategic partnership between CRISPR Therapeutics and Vertex Pharmaceuticals.
  • Vertex leads global development, manufacturing, regulatory and commercialization of CASGEVY with support from CRISPR Therapeutics.
  • CRISPR Therapeutics continues to focus on resource efficiency and return on invested capital as it advances multiple clinical programs across its pipeline.

Beam Therapeutics Highlights Progress Across Base Editing Portfolio and Outlines 2024 Anticipated Milestones

Retrieved on: 
Monday, January 8, 2024
SCD, LNP, Liver, Beam Therapeutics, Pfizer, Conference, Genotype, Sickle cell disease, Gene editing, Second wave, Survival, ESCAPE, Biotechnology, IND, Research, AAT, Pizzicato, Mortality, G6PC, Therapy, Third wave, Clinical trial, Glucose, DSM-IV codes, GMP, Trial of the century, AATD, Transplant, Growth, Investment, Hematology, Stem cell, HBF, Safety, Liver disease, Piz, CTA, Genetic distance, Beam

CAMBRIDGE, Mass., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today reported progress across the company’s hematology and genetic disease portfolios and provided updates on anticipated upcoming milestones.

Key Points: 
  • “Our vision is to establish Beam as a sustainable, fully integrated company pioneering a new class of genetic medicines with base editing.
  • Preclinical models suggest base editing could lead to improved HbF induction and lower residual disease-causing hemoglobin S compared to existing gene therapy options.
  • The company is on-track to report initial data on multiple patients from the BEACON trial in the second half of 2024.
  • Beam expects to report an initial clinical dataset for BEAM-201 in the second half of 2024.

CEPI Partners With Lemonex to Advance mRNA Vaccine Delivery Against Future Pandemic Threats

Retrieved on: 
Monday, January 8, 2024
Biotechnology, Infectious Diseases, COVID-19, Health, Pharmaceutical, RNA, LNP, Disease, Partnership, Risk, Multimedia, Messenger, South Korea, Vaccine, CEPI, Vaccination, Clinical trial, Infection, Temperature, Seoul National University Hospital, Safety, Policy

CEPI has partnered with Lemonex Inc. (Lemonex), a biotechnology company in the Republic of Korea, to advance their mRNA drug delivery technology, DegradaBALL®, which has the potential to both minimise post-mRNA vaccination side effects and improve access to future mRNA vaccines.

Key Points: 
  • CEPI has partnered with Lemonex Inc. (Lemonex), a biotechnology company in the Republic of Korea, to advance their mRNA drug delivery technology, DegradaBALL®, which has the potential to both minimise post-mRNA vaccination side effects and improve access to future mRNA vaccines.
  • (Photo: Lemonex Inc.)
    CEPI is providing Lemonex up to US $4.6 million in funding to evaluate the safety of the DegradaBALL® mRNA vaccine platform in a Phase I clinical study taking place at Seoul National University Hospital.
  • The funding will also support the development of a freeze-dried formulation to reduce complex-cold chain vaccine storage requirements and increase the use of mRNA vaccines in the Global South.
  • Dr. Richard Hatchett, CEO of CEPI, said: “Clinically validated for the first time during the COVID-19 pandemic, mRNA vaccines will be critical if we are to accelerate our responses to future infectious disease threats.